1. Efficacy of pp65‐specific <scp>TCR‐T</scp> cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation
- Author
-
Guangna Liu, Hua Chen, Xingyu Cao, Lemei Jia, Wei Rui, Hongli Zheng, Daosheng Huang, Fang Liu, Yue Liu, Xueqiang Zhao, Peihua Lu, and Xin Lin
- Subjects
Clinical Trials, Phase I as Topic ,HLA-A Antigens ,Hematopoietic Stem Cell Transplantation ,Receptors, Antigen, T-Cell ,Cytomegalovirus ,Hematology ,CD8-Positive T-Lymphocytes ,Phosphoproteins ,Antiviral Agents ,Viral Matrix Proteins ,Epitopes ,Mice ,Cytomegalovirus Infections ,Animals - Abstract
Cytomegalovirus (CMV) infection remains a major cause of mortality after hematopoietic stem cell transplantation (HSCT). Current treatments, including antiviral drugs and adoptive cell therapy with CMV-specific cytotoxic T lymphocytes (CTLs), only show limited benefits in patients. T-cell receptor (TCR)-T cell therapy offers a promising option to treat CMV infections. Here, using tetramer-based screening and single-cell TCR cloning technologies, we identified various CMV antigen-specific TCRs from healthy donors, and generated TCR-T cells targeting multiple pp65 epitopes corresponding to three major HLA-A alleles. The TCR-T cells showed efficient cytotoxicity toward epitope-expressing target cells in vitro. After transfer into immune-deficient mice bearing pp65
- Published
- 2022
- Full Text
- View/download PDF